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SUMMARY
Recently in Northern Ireland there has been a rapid increase in demand for a
variety of blood components. To meet this need a large proportion of routine
blood donations must be processed at the Transfusion Centre. In addition,
several blood components are collected direct from donors by apheresis
techniques. Apheresis is currently restricted to.the collection ofcomponents from
highly selected donors, but in future this method is likely to be employed for
collection of some routine components. This changing pattern is placing
increasing demands on many of our blood donors.
INTRODUCTION
Blood transfusion plays an essential role in modern medicine and surgery. Loss of
blood, whether occurring spontaneously or as a result of trauma, can be rectified
by the transfusion of whole blood or of concentrated red cells, a practice so well
established as to be taken almost for granted. More recently, transfusion of
particular components of blood has been introduced as part of the management
of a wide variety of diseases. Indeed, whereas the usage of red cells has been
increasing slowly, the demand for many of these other blood components has
shown a dramatic upsurge in recent years. This upward trend applies particularly
to platelet concentrates, fresh frozen plasma, and various plasma products,
especially Factor Vill, albumin and certain immunoglobulins.
This development has placed additional burdens on the Blood Transfusion
Service which is responsible for the production of components from donated
blood. The huge increase in demand for blood components means that a high
proportion of blood collected is now processed at the Transfusion Centre
laboratories. The Table summarises the issues of blood and the major blood
components to hospitals in the Province from 1974-84. It can be seen that,
although blood donations have not been increasing during the past 6-7 years, the
usage of most blood components has increased dramatically during the same
period. The exception is cryoprecipitate, the usage ofwhich has decreased as this
product is gradually replaced by freeze-dried concentrates of Factor VIII for the
treatment of haemophilia A. As in the rest of the UK, a proportion of the Factor
Vill concentrate used in the Province has had to be imported, and the sudden
increase in supply during the past year reflects a determined drive to become self-
sufficient in this product.
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.- 0.Demands on blood donors
To meetthedemand for FactorVIII concentrate(and otherfractionated products),
huge quantities of fresh frozen plasma must be collected, currently equivalent to
approximately 35,000 donations per annum. Thisin turn depends on acceptance
by clinicians of plasma-reduced blood for the majority of patients who require red
cell transfusions. The production of purified plasma products requires special
facilities and since 1982 fresh frozen plasma from Northern Ireland has been sent
to the Protein Fractionation Centre, Edinburgh, for processing and purification.
While most blood products can be harvested from ordinary, single-blood
donations, for some components there are advantages in direct collection from
the donor. This applies particularly to those components which are found only
rarely among the blood donor population, e.g. certain specific antibodies, or to
those which are difficult to obtain in sufficiently high yield from conventional
donations, e.g. granulocytes.
The main purpose of this article is to describe the organisation and precautions
involved in setting up specialised blood donor panels for the collection of blood
components and to highlight the increasing demands being placed on these
donors.
APHERESIS
Collection of blood components direct from the donor is carried out by a
procedure called apheresis which allows harvesting of the desired component
while the remainder of the blood is transfused back to the donor. Apheresis
procedures have a number of advantages over ordinary donations for the
collection of components. Thus, not only are larger yields per donation obtained,
but, because there is no significant red cell loss, donation can be carried out more
frequently (commonly at monthly intervals). Apheresis can be carried out either
manually, using a centrifuge to isolate the required component, or mechanically,
using specially designed cell-separator machines. A large number of the latter
devices which can be used to collect plasma, platelets or white cells direct from
donors are now available. Although these procedures have become well
established and are considered safe, they do tend to be fairly prolonged and
entail having a needle in situ (one or both arms) for periods varying from 45
minutes to two hours. Furthermore, certain types of donors (e.g. anti-D donors)
require to be immunised with foreign material prior to apheresis.
During the past few years, many apheresis donors have been recruited by the
Northern Ireland Blood Transfusion Service. These donors are organised into
separate panels according to the products obtained from their donations, i.e. cells
(granulocytes and platelets), anti-D and other specific immunoglobulins.
GRANULOCYTES AND PLATELETS
Granulocyte transfusion is sometimes indicated for infected patients who are also
severely granulocytopaenic. The need for transfusion arises particularly during
the treatmentof leukaemia when severe bacterial infection, which is unresponsive
to antibiotics, is present. To make it effective, a large quantity of white cells is
required, and this is best obtained by cytopheresis, using the automated cell-
separator machine sited in the Royal Victoria Hospital.
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Platelets are normally obtained from single donations, but certain patients who
become refractory to random-donor platelets may require platelets from HLA-
matched donors. Invariably very few of the latter will be available, so the most
practical method of collection is by plateletpheresis.
Granulocytes and single-donor platelets may be donated by relatives of the
patient concerned. However, in many cases, suitable relatives cannot be found,
and so in 1980 the NIBTS began recruitment of a panel of volunteers from the
blood donor population. In order to avoid exerting undue moral pressure on
existing donors, recruitment was carried out by a general publicity campaign
rather than by a direct approach to individuals.
A code of practice for the organisation of such a panel of volunteers has been
produced l to which strict adherence is required. Before being admitted to the
donor panel, each potential volunteer is provided with a detailed explanation of
the procedure, including full information about any risks involved. The approval
of their general practitioner is also sought. Those wishing to proceed are then
asked to sign a consent form. Most donors are under the age of 40; this is
desirable, as donors over this age should, according to the code of practice, have
an ECG and chest X-ray prior to each donation. The donor panel has at present
about 200 members who provide around 60 donations of granulocytes and/or
platelets per year.
ANTI-D IMMUNOGLOBULIN
The almost complete prevention of haemolytic disease of the newborn by the
routine administration of anti-D immunoglobulin to all Rhesus (D) negative
women soon after the delivery of a Rhesus-positive baby (introduced in 1968)
has been a major medical advance. The success ofthis programme has, however,
led to some problems in providing the raw material (human plasma containing
high titre anti-D) from which the immunoglobulin is produced. Until recently, the
major source of this plasma were those Rhesus-negative women who had
produced anti-D as a result of pregnancy. Now that this is successfully prevented
in most cases, such individuals have become very few in number. The only
alternative source is Rhesus-negative men who volunteer to be deliberately
immunised with Rhesus-positive blood, soas tostimulate the productionofanti-D
antibodies. A panel of such donors has been recruited during the past year by the
NIBTS in order to meet the demand for anti-D immunoglobulin in the Province.
As with cell donors, no direct approach was made to recruit existing donors to the
panel, and fully informed written consent was obtained before admission. Since
the procedure involves the administration of repeated small blood transfusions
(1 -2 ml), rigorous precautions must be taken to,ensure that potential side-effects,
e.g. hepatitis, production of unwanted red cell antibodies, etc., are prevented.
Thus, in addition to the usual pre-donation tests, blood used for immunisation is
selected from a specially accredited donor panel. The latter have exhaustive and
frequent tests carried out to ensure as far as possible that their blood will not
transmit any of the hepatitis viruses. Furthermore, the donor and recipient are
matched for all clinically significant blood groups apart from the Rhesus (D)
antigen. This is to ensure that no unwanted red cell antibodies are produced
which might increase the difficulty in obtaining compatible blood, should the
individual ever require a blood transfusion. To this end, volunteers are also
encouraged to wear an identity bracelet which is designed to alert their medical
attendants to the importance of transfusing Rhesus-negative blood.
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Once the anti-D titre has reached a sufficiently high level, plasma is collected by
apheresis at about monthly intervals. Approximately 300 plasma donations per
annum are required to meet current demand in the Province. This plasma is sent
to the Protein Fractionation Centre, Edinburgh, for processing to anti-D
immunoglobulin.
The future may see the introduction of antenatal prophylaxis of all Rhesus-
negative women (to cover the occasional cases where antibodies are produced
during pregnancy).2 This practice has been shown to be effective, but while
clinically desirable, it would cause an enormous (fourfold) increase in the require-
ment for anti-D and consequently for many more immunised donors. Some
would argue that the risks to donors (although extremely small) do notjustify the
relatively small benefit which might result.3
OTHER SPECIFIC IMMUNOGLOBULINS
In addition to anti-D, a number of other specific immunoglobulins are produced
from human plasma containing a high titre of the appropriate antibody. These
include anti-Hepatitis B, anti-Tetanus and anti-Varicella Zoster, etc., which are
used for post-exposure prophylaxis in certain 'at risk' individuals. Suitable donors
ofthe source plasma are extremely scarce, so, when identified by prior laboratory
testing, they are encouraged to donate by plasmapheresis. About 300 such
donations are collected per annum.
FUTURE DEVELOPMENTS
As indicated above, apheresis procedures have been used hitherto on a small
scale, being restricted to highly selected donors. This is likely to change in the
near future as the demand for blood components (e.g. platelet concentrates and
certain plasma products) normally collected from random donors, continues to
increase rapidly. Since the demand for red cells is growing much more slowly, it
seems logical to augment supplies ofthese non-red cell products by the adoption
of apheresis procedures on a proportion of the normal blood donor population.
Until recently, the methods available have been too cumbersome, slow and costly
to allow apheresis to be used on a large scale. Devices are now being produced
which make this much more feasible and have already been used for the
collection of large volumes of platelets and plasma in some centres.4
It is likely that the demand for blood components will continue to increase at least
in the short-term. Eventually, it is quite possible, as developments in genetic
engineering enable some of these products to be synthesised, that the require-
ment for blood components of human origin will decrease.
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